FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2244811147> ?p ?o ?g. }

• W2244811147 abstract "11087 Background: To evaluate prognostic factors for disease-free survival (DFS) following NST with G, E and Doc of patients with PBC. Methods: From 1/02 to 12/04 113 patients with T2–4 N0–2 M0 PBC received either six cycles of GEDoc (G 800 mg/m 2 day (d) 1+8, E 60–90 mg/m 2 d 1, Doc 60–75 mg/m 2 d 1 every three weeks; 63 patients) or five cycles of GE (1,250 mg/m 2 d 1, E 90–100 mg/m 2 d 1 every two weeks) sequentially followed by four cycles of Doc (80–100 mg/m 2 d 1every two weeks) with prophylactic filgrastim. 71% of tumours were hormone receptor positive, 24% HER2 positive (3+ by immunohistochemistry), 46% grade 3. 28 patients (25%) achieved a pathologic complete response (pCR) defined as no invasive tumour residue in the removed breast tissue at surgery. 9 of these patients had non-invasive cancer residues in the breast, one patient showed persisting axillary lymph node involvement. Results: With a median follow up of 3.2 years there is no statistically significant difference in DFS, distant DFS (DDFS) and overall survival (OS) rates between patients with and without pCR (DFS 79 versus (vs) 81 %, p=0,61; DDFS 82 vs 84 %, p=0.69; OS 86 vs 91%, p=0.33). In a Cox proportional hazards model HER2 3+ before NST (hazard ratio (HR)= 4.7; 95% confidence interval (CI) 1.9 - 11.3; p=0.0006), positive hormone receptors before NST (HR=0.27; 95% CI 0.11 - 0.65; p=0.003) and clinically nodal involvement before NST (HR=3.3; 95% CI 1.2–9.1; p=0.02) were statistically significant prognostic factors for recurrence whereas tumour size and grade before NST, the achievement of pCR, nodal status at surgery and response after 6 weeks of NST did not reach statistical significance. Thus far, in multivariate analysis only Her2 3+ before NST retained its prognostic significance (HR= 2.8; 95% CI 1.03 - 7.5, p=0.04). Conclusions: With a median follow-up of 3.2 years in multivariate analysis only HER2 3+ is associated with shorter DFS following NST containing G, E and Doc for PBC. Thus far, there is no statistically significant prognostic value for pCR. No significant financial relationships to disclose." @default.
• W2244811147 created "2016-06-24" @default.
• W2244811147 creator A5002219591 @default.
• W2244811147 creator A5011232197 @default.
• W2244811147 creator A5018949334 @default.
• W2244811147 creator A5069383705 @default.
• W2244811147 creator A5071893291 @default.
• W2244811147 creator A5084545133 @default.
• W2244811147 creator A5089392438 @default.
• W2244811147 date "2007-06-20" @default.
• W2244811147 modified "2023-09-27" @default.
• W2244811147 title "HER2 overexpression is associated with shorter disease-free survival (DFS) following neoadjuvant systemic therapy (NST) of primary breast cancer (PBC) patients with gemcitabine (G), epirubicin (E) and docetaxel (Doc)" @default.
• W2244811147 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.11087" @default.
• W2244811147 hasPublicationYear "2007" @default.
• W2244811147 type Work @default.
• W2244811147 sameAs 2244811147 @default.
• W2244811147 citedByCount "0" @default.
• W2244811147 crossrefType "journal-article" @default.
• W2244811147 hasAuthorship W2244811147A5002219591 @default.
• W2244811147 hasAuthorship W2244811147A5011232197 @default.
• W2244811147 hasAuthorship W2244811147A5018949334 @default.
• W2244811147 hasAuthorship W2244811147A5069383705 @default.
• W2244811147 hasAuthorship W2244811147A5071893291 @default.
• W2244811147 hasAuthorship W2244811147A5084545133 @default.
• W2244811147 hasAuthorship W2244811147A5089392438 @default.
• W2244811147 hasConcept C121608353 @default.
• W2244811147 hasConcept C126322002 @default.
• W2244811147 hasConcept C143998085 @default.
• W2244811147 hasConcept C185926286 @default.
• W2244811147 hasConcept C2776694085 @default.
• W2244811147 hasConcept C2778292576 @default.
• W2244811147 hasConcept C2779786085 @default.
• W2244811147 hasConcept C2780258809 @default.
• W2244811147 hasConcept C2780835546 @default.
• W2244811147 hasConcept C2781190966 @default.
• W2244811147 hasConcept C530470458 @default.
• W2244811147 hasConcept C71924100 @default.
• W2244811147 hasConceptScore W2244811147C121608353 @default.
• W2244811147 hasConceptScore W2244811147C126322002 @default.
• W2244811147 hasConceptScore W2244811147C143998085 @default.
• W2244811147 hasConceptScore W2244811147C185926286 @default.
• W2244811147 hasConceptScore W2244811147C2776694085 @default.
• W2244811147 hasConceptScore W2244811147C2778292576 @default.
• W2244811147 hasConceptScore W2244811147C2779786085 @default.
• W2244811147 hasConceptScore W2244811147C2780258809 @default.
• W2244811147 hasConceptScore W2244811147C2780835546 @default.
• W2244811147 hasConceptScore W2244811147C2781190966 @default.
• W2244811147 hasConceptScore W2244811147C530470458 @default.
• W2244811147 hasConceptScore W2244811147C71924100 @default.
• W2244811147 hasLocation W22448111471 @default.
• W2244811147 hasOpenAccess W2244811147 @default.
• W2244811147 hasPrimaryLocation W22448111471 @default.
• W2244811147 hasRelatedWork W1972094548 @default.
• W2244811147 hasRelatedWork W1975750848 @default.
• W2244811147 hasRelatedWork W2060666847 @default.
• W2244811147 hasRelatedWork W2077774632 @default.
• W2244811147 hasRelatedWork W2343768426 @default.
• W2244811147 hasRelatedWork W2795212278 @default.
• W2244811147 hasRelatedWork W3046986536 @default.
• W2244811147 hasRelatedWork W3135713841 @default.
• W2244811147 hasRelatedWork W4281560766 @default.
• W2244811147 hasRelatedWork W4289766408 @default.
• W2244811147 isParatext "false" @default.
• W2244811147 isRetracted "false" @default.
• W2244811147 magId "2244811147" @default.
• W2244811147 workType "article" @default.